Skip to main content
. Author manuscript; available in PMC: 2021 Dec 1.
Published in final edited form as: Biochim Biophys Acta Rev Cancer. 2020 Oct 6;1874(2):188447. doi: 10.1016/j.bbcan.2020.188447

Fig. 2.

Fig. 2.

Comparison between dMMR/MSI-H and pMMR/MSS colorectal cancers. dMMR/MSI-H CRCs have a high mutational burden and persistent renewal of neoantigens, which is favorable for immune surveillance, while pMMR/MSS CRCs have a low mutational burden and lack immune surveillance.